期刊文献+

甲磺酸加替沙星与其他4种氟喹诺酮类药物对临床分离菌的体外抗菌活性比较 被引量:5

Comparison of in vitro activity of gatifloxacin and other four fluoquinolones against clinical isolates
下载PDF
导出
摘要 目的 :比较甲磺酸加替沙星与氧氟沙星、左氧沙星、环丙沙星、司帕沙星对 182株临床分离菌的体外抗菌活性。方法 :采用琼脂平板二倍稀释法测定加替沙星等 5种氟喹诺酮类药物对 182株临床试验分离菌株的最低抑菌浓度 (MIC)。结果 :加替沙星对葡萄球菌属的MIC90 比其他 4种氟喹诺酮类药物低。葡萄球菌属对加替沙星的敏感率显著高于其他4种氟喹诺酮类药物 ;对其他G+球菌的MICR 也较其他氟喹诺酮类药物低。G-杆菌中埃希菌属、肠杆菌属对加替沙星的敏感率明显高于其他 4种氟喹诺酮类药物 ,加替沙星对埃希菌属、肠杆菌属的MIC90比左氧沙星低 2倍 ,比其他 3种抗菌药物低 8倍 ;假单胞菌属、克雷伯菌属和其他G-杆菌对加替沙星的敏感率与左氧沙星的差异无统计学意义 ,与其他 3种氟喹诺酮类药物的差异有统计学意义。结论 :甲磺酸加替沙星具有广谱而强大的体外抗菌活性。 AIM: To compare in vitro activity of gatifloxacin against 182 clinical isolated pathogens with those of ciprofloxacin, ofloxacin, levofloxacin and sparfloxacin. METHODS: The MICs of 182 clinical isolated pathogens were determined by the two fold agar dilution method. RESULTS: The MIC 90 of gatifloxacin against staphylococcus species was lower than the other four fluoquinolones. The ratio of sensitivity of staphylococcus species to gatifloxacin was higher than the other four fluoquinolones; the MIC R of gatifloxacin against other gram positive cocci was lower than the other four fluoquinolones. The ratios of sensitivity of gram negative bacilli, such as Escherichia species and Enterobacter species to gatifloxacin were higher than the other four fluoquinolones; The MIC 90 of gatifloxacin against escherichia species and enterobacter species was 2 fold lower than levofloxacin and 8 fold lower than the other 3 fluoquinolones. The ratios of sensitivity of pseudomonas species, klebsiella species and other gram negative bacilli to gatifloxacin had no significance with levofloxacin and were higher than ciprofloxacin, ofloxacin, and sparfloxacin. CONCLUSION: In vitro activity of gatifloxacin against common clinical bacterium is strong.
出处 《中国临床药理学与治疗学》 CAS CSCD 2004年第1期48-51,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 加替沙星 体外抗菌活性 氟喹诺酮类 临床分离菌 gatifloxacin in vitro activity fluoquinolones clinical isolates
  • 相关文献

参考文献7

  • 1[1]Dennis M, Grasel S. Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clinical Infect Dis, 2000;31:S51-8
  • 2[2]Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activities of AM-1166, a new 6-fluoro-8-methoxyquinolone[J]. Antimicrob Agents Chemother, 1992;36:2108-17
  • 3[3]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activities of AM-1155, a novel 6-fluoro-8-methoxyquinolone[J].Antimicrob Agents Chemother, 1994;38:594-601
  • 4[4]Jones RN, Biedenbach DJ, Erwin ME, Beach ML, Pfaller MA. Activity of gatifloxacin against haemophilus influenzae and moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae[J]. J Clin Microbiol, 1999;37:1999-2002
  • 5[5]National Commettee for Clinical Laboratory Standards[S]. 2002:99-103
  • 6[6]Pfaller MA, Jones RN, Doern GV, Salazar JC. Survey of blood stream infections attribute to gram-positive cocci :frequency of occurrence and antimicrobial susceptibility of isolates collected 1997 in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program[J].Diagn Microbiol Infect Dis, 1999;33:283-97
  • 7[7]Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN,et al. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999[J].Clin Infect Dis, 2001;32:( Suppl 2):S114-32

同被引文献21

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部